Octreotide long-acting injection(CSPC)

奥曲肽长效注射液（石药）

Report date: 2026/04/28 20:00:22

Base Information

Drug NameOctreotide long-acting injection(CSPC)
Drug Alias Name奥曲肽 (石药)奥曲肽长效注射液（2.2类改良型）
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGrowth hormone releasing factor antagonistsSomatostatin receptor agonists
TargetsSomatostatin receptorGrowth hormone releasing factor
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)AcromegalyNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic neuroendocrine tumors (pNET)AcromegalyNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A